Download by
Scanning QR Code
No Data
CN Stock MarketDetailed Quotes
000411 Zhejiang Int'l Group
Watchlist
12.08
+0.06+0.50%
Market Closed 09/22 15:00 CST
12.10High11.91Low58.25KlotVolume
12.02Open12.02Pre Close69.92MTurnover1.94%Turnover Ratio16.26P/E (TTM)6.11BMarket Cap16.7652wk High28.76P/E (Static)505.46MShares9.1952wk Low1.62P/B3.63BFloat Cap36.07Historical High13.22Limit Up300.85MShs Float1.07Historical Low10.82Limit Down1.58%Amplitude30.86KlotAsk0.13Dividend TTM12.00Avg Price27.16KlotBid1.04%Div YieldTTM100Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Zhejiang Int'l Group Company
The company is a listed company under the Zhejiang International Trade Group controlled by the Zhejiang Provincial State-owned Assets Administration Commission (stock code SZ.000411). The company, formerly known as Zhejiang People's Pharmaceutical Company, which was founded in 1950, achieved backdoor listing in 2001, China Sinochem Group joined Intel Group in 2008, returned to Zhejiang Province in 2017, and managed by Zhejiang International Trade Group. The company is one of the leading regional enterprises in the pharmaceutical distribution industry in Zhejiang Province. It is mainly engaged in the wholesale and retail business of pharmaceuticals and medical devices, that is, it purchases products from upstream pharmaceutical manufacturers or suppliers, and then sells them to downstream medical institutions, pharmacies, dealers, etc., or directly to consumers through retail terminals. The company's main business is the wholesale and retail business of pharmaceutical-related products, covering various categories of products such as pharmaceuticals and medical devices. Among them, the wholesale business is the main sales business, and pharmaceuticals are the most important sales products. The major categories of pharmaceuticals include chemical drugs, biological products, proprietary Chinese medicines, Chinese medicine tablets, etc.; the major categories of medical devices include medical devices, diagnostic reagents, medical consumables, etc. Corporate honors: The company has always maintained steady management and standardized governance. It has won the top 30 internal control companies in Zhejiang for 3 consecutive years. In addition, it has also won many honorary titles such as “Pharmaceutical Industry Benchmarking Enterprise in the 70th Anniversary of the Founding of New China”, “Top 500 Chinese Service Enterprises”, and “Zhejiang's First Batch of Provincial Supply Chain Innovation and Application Enterprises”.
News
Intel Group (000411.SZ): Gross margin for the second quarter of 2023 was higher than the first quarter
GLONGHUI, September 4 | In response to investor research, Intel Group (000411.SZ) said that there are two reasons why the company's gross margin in the second quarter of 2023 was higher than in the first quarter: first, the company's stock business structure changed, and the share of business with relatively high gross margin increased; second, the incremental volume brought about by Baishan Medical, etc. of new mergers and acquisitions was included in the consolidated report. The gross margin of the new M&A companies was higher than the company average.
Interpretation of Intel Group's 2023 Interim Report: Net Profit Increased Significantly, Balance Sheet and Cash Flow Statement Performance Steady
According to Intel Group's 2023 interim report, revenue for the reporting period was 16,002,063,040.83 yuan, an increase of 9.23% over 14,650,227,368.93 yuan in the same period last year. This shows that the company has performed well in market competition and has maintained steady growth in operating income. Meanwhile, net profit attributable to shareholders of listed companies during the reporting period was 278,011,103.63 yuan, an increase of 142.27% compared to 114,753,204.30 yuan in the same period last year. This is a very significant increase, indicating that the company's profitability has been significant
Intel Group (000411.SZ): Net profit increased 142.27% in the first half of the year to 278 million yuan
Glonghui, August 25 | Intel Group (000411.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 16.02 billion yuan, up 9.23% year on year; net profit attributable to shareholders of listed companies was 278 million yuan, up 142.27% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 205 million yuan, up 88.83% year on year; basic earnings per share were 0.64 yuan.